Howard L. McLeod, PharmD

Where You Are:
Howard L. McLeod, PharmD

Senior Member

Office  (813) 745-8435

Education And Training
  • Research Fellow, University of Glasgow, 1993 - Medical Oncology
  • Fellow, St. Jude Children's Research Hospital, 1992 - Clinical Research
  • Pharm.D., Philadelphia College of Pharmacy and Science, 1990


  • Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype. Clin Pharmacol Ther. 2014 Aug;96(2):169-174. Pubmedid: 24787449.
  • Hariani GD, Lamm E, Havener T, Kwok P, McLeod HL, Wagner MJ, Motsinger-Reif AA. Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes. 2014 Jun;7(1):360. Pubmedid: 24924344. Pmcid: PMC4068968.
  • Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvin Jr WJ. Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics. 2014 May;17(1):43-47. Pubmedid: 24457521. Pmcid: PMC4058990.
  • Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat. 2014 May;145(1):245-254. Pubmedid: 24706167.
  • Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014 May;20(10):2530-2540. Pubmedid: 24831276.
  • Liu MZ, McLeod HL, He FZ, Chen XP, Zhou HH, Shu Y, Zhang W. Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics. 2014 Apr;15(5):699-715. Pubmedid: 24798726.
  • Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Astrup Jensen S, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014 Apr;32(10):1031-1039. Pubmedid: 24590654.
  • Ferreri SP, Greco AJ, Michaels NM, O'Connor SK, Chater RW, Viera AJ, Faruki H, McLeod HL, Roederer MW. Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003). 2014 Mar;54(2):172-180. Pubmedid: 24632932.
  • Ramos EM, Din-Lovinescu C, Berg JS, Brooks LD, Duncanson A, Dunn M, Good P, Hubbard TJ, Jarvik GP, O'Donnell C, Sherry ST, Aronson N, Biesecker LG, Blumberg B, Calonge N, Colhoun HM, Epstein RS, Flicek P, Gordon ES, Green ED, Green RC, Hurles M, Kawamoto K, Knaus W, Ledbetter DH, Levy HP, Lyon E, Maglott D, McLeod HL, Rahman N, Randhawa G, Wicklund C, Manolio TA, Chisholm RL, Williams MS. Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet. 2014 Mar;166(1):93-104. Pubmedid: 24634402.
  • Brown CC, Havener TM, Medina MW, Jack JR, Krauss RM, McLeod HL, Motsinger-Reif AA. Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics. 2014 Feb;15(2):137-146. Pubmedid: 24444404.
  • Patel JN, Mandock K, McLeod HL. Clinically relevant cancer biomarkers and pharmacogenetic assays. J Oncol Pharm Pract. 2014 Feb;20(1):65-72. Pubmedid: 23353710.
  • Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014 Feb. Pubmedid: 24513692.
  • Shen J, Yin JY, Li XP, Liu ZQ, Wang Y, Chen J, Qu J, Xu XJ, McLeod HL, He YJ, Xia K, Jia YW, Zhou HH. The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers. PLoS One. 2014;9(4):e96008. Pubmedid: 24789280.
  • Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. PLoS One. 2014;9(4):e94727. Pubmedid: 24727911.
  • Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014 Jun. Pubmedid: 24918167.
  • Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013 Dec;94(6):640-645. Pubmedid: 23988873. Pmcid: PMC3831181.
  • McWhinney-Glass S, Winham SJ, Hertz DL, Yen Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, McLeod HL. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res. 2013 Oct;19(20):5769-5776. Pubmedid: 23963862. Pmcid: PMC3798385.
  • Jonas DE, Evans JP, McLeod HL, Brode S, Lange LA, Young ML, Shilliday BB, Bardsley MM, Swinton-Jenkins NJ, Weck KE. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013 Oct;14(13):1593-1603. Pubmedid: 24088130.
  • Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol. 2013 Sep;76(3):370-380. Pubmedid: 23701381. Pmcid: PMC3769665.
  • Smith CG, Naven M, Harris R, Colley J, West H, Li N, Liu Y, Adams R, Maughan TS, Nichols L, Kaplan R, Wagner MJ, McLeod HL, Cheadle JP. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Hum Mutat. 2013 Jul;34(7):1026-1034. Pubmedid: 23585368.
  • Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ. 2013 Jul;1:e31. Pubmedid: 23638367. Pmcid: PMC3628892.
  • Patel JN, Fuchs CS, Owzar K, Chen Z, McLeod HL. Gastric cancer pharmacogenetics: progress or old tripe?. Pharmacogenomics. 2013 Jul;14(9):1053-1064. Pubmedid: 23837480.
  • McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013 Jun;5(189):189sr4. Pubmedid: 23761042.
  • Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?. Curr Oncol Rep. 2013 Jun;15(3):276-285. Pubmedid: 23512709. Pmcid: PMC3644374.
  • Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemostasis. 2013 Jun;109(6):1045-1050. Pubmedid: 23571513. Pmcid: PMC3712827.
  • Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013 Jun;24(6):1472-1478. Pubmedid: 23413280. Pmcid: PMC3660078.
  • Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet. 2013 May;58(6):346-352. Pubmedid: 23677053.
  • Brown CC, Havener TM, Medina MW, Krauss RM, McLeod HL, Motsinger-Reif AA. Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Min. 2013 May;5(1):21. Pubmedid: 23234571. Pmcid: PMC3661384.
  • Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013 May;139(1):135-143. Pubmedid: 23588952. Pmcid: PMC3673300.
  • Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, Marinaki T, McLeod HL, Relling MV, Schaeffeler E, Schwab M, Weinshilboum R, Yeoh AE, McDonagh EM, Hebert JM, Klein TE, Coulthard SA. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013 Apr;23(4):242-248. Pubmedid: 23407052. Pmcid: PMC3727893.
  • He FZ, McLeod HL, Zhang W. Current pharmacogenomic studies on hERG potassium channels. Trends Mol Med. 2013 Apr;19(4):227-238. Pubmedid: 23369369.
  • Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics. 2013 Apr;14(5):555-574. Pubmedid: 23556452. Pmcid: PMC3975654.
  • Gurwitz D, McLeod HL. Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics. 2013 Mar;14(4):337-339. Pubmedid: 23438876.
  • McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science. 2013 Mar;339(6127):1563-1566. Pubmedid: 23539596. Pmcid: PMC3900028.
  • Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan;23(1):29-33. Pubmedid: 23188068. Pmcid: PMC3647228.
  • Jensen BC, McLeod HL. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013 Jan;14(2):205-213. Pubmedid: 23327580. Pmcid: PMC3582022.
  • Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of data. Oncologist. 2013 Jan;17(5):620-630. Pubmedid: 22531359. Pmcid: PMC3360902.
  • Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, Krauss RM, McLeod HL, Motsinger-Reif AA. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics. 2012 Nov;22(11):796-802. Pubmedid: 23047291. Pmcid: PMC3691078.
  • He YJ, McLeod HL. Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther. 2012 Oct;92(4):412-414. Pubmedid: 22992667.
  • Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012 Sep;17(3):296-302. Pubmedid: 22382460. Pmcid: PMC3316912.
  • Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep;18(18):5099-5109. Pubmedid: 22843789. Pmcid: PMC3445665.
  • He YJ, Misher AD, Irvin W, Motsinger-Reif A, McLeod HL, Hoskins JM. Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. Clin Chem Lab Med. 2012 Aug;50(8):1329-1334. Pubmedid: 22868796.
  • Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug;104(16):1264. Pubmedid: 22851270.
  • Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-410. Pubmedid: 22527101. Pmcid: PMC3727245.
  • Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-117. Pubmedid: 22617227. Pmcid: PMC3384438.
  • Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, Coleman CA, Wolfe M, Sandler RS, McLeod HL. Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One. 2012 Jul;7(7):e41954. Pubmedid: 22848671. Pmcid: PMC3407042.
  • Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE, van den Oord E, Bogue MA, Yang H, Wang W, Threadgill DW, de Villena FP, McLeod HL, Sullivan PF. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome. 2012 Jun;23(5-6):322-335. Pubmedid: 22207321. Pmcid: PMC3356790.
  • O'Connor SK, Ferreri SP, Michaels NM, Greco AJ, Viera AJ, Faruki H, McLeod HL, Roederer MW. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics. 2012 Jun;13(8):955-962. Pubmedid: 22676199.
  • Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy?. Bull World Health Organ. 2012 Apr;89(11):838-845. Pubmedid: 22084530. Pmcid: PMC3209725.
  • He YJ, Shapero MH, McLeod HL. Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenet Genomics. 2012 Apr;22(4):322-324. Pubmedid: 22414877. Pmcid: PMC3306057.
  • Walko CM, McLeod H. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. Pharmacogenomics. 2012 Apr;13(6):691-697. Pubmedid: 22515611.
  • Crowley JJ, Adkins DE, Pratt AL, Quackenbush CR, van den Oord EJ, Moy SS, Wilhelmsen KC, Cooper TB, Bogue MA, McLeod HL, Sullivan PF. Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J. 2012 Apr;12(2):147-155. Pubmedid: 21079646. Pmcid: PMC3117923.
  • Talameh JA, McLeod HL, Adams KF, Patterson JH. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail. 2012 Apr;18(4):338-349. Pubmedid: 22464776.
  • Won HH, Kim SR, Bang OY, Lee SC, Huh W, Ko JW, Kim HG, McLeod HL, O'Connell TM, Kim JW, Lee SY. Differentially expressed genes in human peripheral blood as potential markers for statin response. J Mol Med (Berl). 2012 Feb;90(2):201-211. Pubmedid: 21947165.
  • Hutz JE, Manning WA, Province MA, McLeod HL. Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. PLoS One. 2012 Jan;6(9):e24873. Pubmedid: 21949775. Pmcid: PMC3176272.
  • Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan;18(2):577-584. Pubmedid: 22142827. Pmcid: PMC3412624.
  • Talameh JA, McLeod HL. PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?. Clin Pharmacol Ther. 2011 Dec;90(6):771-774. Pubmedid: 22089342.
  • Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer. 2011 Nov;105(11):1654-1662. Pubmedid: 22045187. Pmcid: PMC3242600.
  • Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011 Oct;21(10):679-686. Pubmedid: 21317831. Pmcid: PMC3139712.
  • Watson VG, Hardison NE, Harris T, Motsinger-Reif A, McLeod HL. Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther. 2011 Oct;10(10):1839-1845. Pubmedid: 21750217. Pmcid: PMC3191307.
  • Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, Wagner M, Richards KL, Province MA, McLeod HL. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics. 2011 Oct;12(10):1407-1415. Pubmedid: 22008047. Pmcid: PMC3399590.
  • Watson VG, Motsinger-Reif A, Hardison NE, Peters EJ, Havener TM, Everitt L, Auman JT, Comins DL, McLeod HL. Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PLoS One. 2011 Oct;6(5):e17561. Pubmedid: 21573211. Pmcid: PMC3088663.
  • McLeod HL, Tortora G, Rowett LH, Vermorken JB. Found in translation: annals of oncology and translational research. Ann Oncol. 2011 Aug;22(8):1698-1699. Pubmedid: 21795324.
  • Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011 Aug;29(24):3232-3239. Pubmedid: 21768473. Pmcid: PMC3158597.
  • Beitelshees AL, Johnson JA, Hames ML, Gong Y, Cooper-Dehoff RM, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS One. 2011 Jul;5(12):e15180. Pubmedid: 21170323. Pmcid: PMC3000815.
  • Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011 Jul;21(7):440-446. Pubmedid: 21048526. Pmcid: PMC3116111.
  • Kolesar JM, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, Keller SM, Schiller JH. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep. 2011 Jun;25(6):1765-1772. Pubmedid: 21479364. Pmcid: PMC3211091.
  • McLeod HL, Isaacs KL. Preemptive pharmacogenetic testing: insufficient data equal unsatisfactory guidance. Ann Intern Med. 2011 Jun;154(12):842-844. Pubmedid: 21690601.
  • Roederer MW, Sanchez-Giron F, Kalideen K, Kudzi W, McLeod HL, Zhang W. Pharmacogenetics and rational drug use around the world. Pharmacogenomics. 2011 Jun;12(6):897-905. Pubmedid: 21692619.
  • Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-1237. Pubmedid: 20694727. Pmcid: PMC3102212.
  • Carvalho L, Yu J, Schwartsmann G, McLeod HL, Fleshman JW. RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncol Rep. 2011 May;25(5):1321-1327. Pubmedid: 21380492. Pmcid: PMC3954856.
  • He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med. 2011 May;17(5):244-251. Pubmedid: 21388883. Pmcid: PMC3092840.
  • Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011 Apr;21(4):237-242. Pubmedid: 20601926. Pmcid: PMC3098754.
  • Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011 Mar;364(12):1144-1153. Pubmedid: 21428770. Pmcid: PMC3184612.
  • Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol. 2011 Mar;29(7):875-883. Pubmedid: 21205745. Pmcid: PMC3068061.
  • Muhale FA, Wetmore BA, Thomas RS, McLeod HL. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011 Mar;12(3):341-350. Pubmedid: 21449674. Pmcid: PMC3124653.
  • Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW, Kelly DP, Spertus JA, McLeod HL. A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One. 2011 Feb;5(9):e12584. Pubmedid: 20838448. Pmcid: PMC2933242.
  • Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol. 2011 Jan;223(1):15-27. Pubmedid: 20818641.
  • Brown C, Havener TM, Everitt L, McLeod H, Motsinger-Reif AA. A comparison of association methods for cytotoxicity mapping in pharmacogenomics. Front Genet. 2011;2:86. Pubmedid: 22303380. Pmcid: PMC3268638.
  • Warner A, Nelsen A, Bhathena A, Fitzgerald K, Gilardi S, Kelso E, Knoppers B, McLeod HL, Nelson R, Uyama Y, Weisman J, Rudman A. Enabling pharmacogenomic clinical trials through sampling. Pharmacogenomics. 2010 Dec;11(12):1649-1654. Pubmedid: 21142907.
  • Thomas F, Hoskins JM, Dvorak A, Tan BR, McLeod HL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics. 2010 Dec;11(12):1751-1756. Pubmedid: 21142919. Pmcid: PMC3128643.
  • Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodríguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010 Dec;54(12):5242-5250. Pubmedid: 20921307. Pmcid: PMC2981241.
  • Watson RG, Muhale F, Thorne LB, Yu J, O'Neil BH, Hoskins JM, Meyers MO, Deal AM, Ibrahim JG, Hudson ML, Walko CM, McLeod HL, Auman JT. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer. 2010 Dec;46(18):3358-3364. Pubmedid: 20727737. Pmcid: PMC2991554.
  • Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov;102(22):1698-1705. Pubmedid: 20944079. Pmcid: PMC2982809.
  • Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilboum RM, Relling MV, Evans WE, Klein TE, Altman RB. Thiopurine pathway. Pharmacogenet Genomics. 2010 Sep;20(9):573-574. Pubmedid: 19952870. Pmcid: PMC3098750.
  • McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul;28(20):3227-3233. Pubmedid: 20530282. Pmcid: PMC2903324.
  • McLeod HL. Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. Heart Fail Rev. 2010 May;15(3):183-185. Pubmedid: 19578990.
  • Roederer MW, McLeod HL. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics. 2010 May;11(5):633-636. Pubmedid: 20415551.
  • Ranganathan P, McLeod H. Race and methotrexate pharmacogenetics in rheumatoid arthritis. J Rheum. 2010 May;37(5):1064. Pubmedid: 20439524.
  • Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, McLeod HL, Weichselbaum RR, Ratain MJ, Altman RB, Klein TE. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May;20(5):346-349. Pubmedid: 20124951. Pmcid: PMC3086058.
  • Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-281. Pubmedid: 20150829. Pmcid: PMC3201766.
  • Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010 Apr;87(4):445-451. Pubmedid: 20200517. Pmcid: PMC2928561.
  • Auman JT, McLeod HL. Now's the time to find biomarkers on purpose. Ann Oncol. 2010 Feb;21(2):193-194. Pubmedid: 20047974.
  • Auman JT, McLeod HL. Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. Clin Colorectal Cancer. 2010 Jan;9(1):40-47. Pubmedid: 20100687.
  • Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, Riper Mv, Vernon JA, Zamboni WC, Wagner MJ, Walko CM, Weck KE, Wiltshire T, McLeod HL. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics. 2010 Jan;11(1):13-21. Pubmedid: 20017668.
  • Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010 Jan;8(1):95-100. Pubmedid: 19874474. Pmcid: PMC3718044.
  • Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc. 2010;121:21-32. Pubmedid: 20697547. Pmcid: PMC2917134.
  • Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol. 2010;50:423-437. Pubmedid: 20055709.
  • Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet Genomics. 2009 Dec;19(12):979-983. Pubmedid: 21151855. Pmcid: PMC2998989.
  • Yen-Revollo JL, Van Booven DJ, Peters EJ, Hoskins JM, Engen RM, Kannall HD, Ofori-Adjei D, McLeod HL, Marsh S. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J. 2009 Dec;9(6):373-379. Pubmedid: 19546880.
  • Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009 Dec;61(4):413-429. Pubmedid: 20038569. Pmcid: PMC2802425.
  • Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009 Nov;10(11):1799-1817. Pubmedid: 19891556.
  • Lee SC, Xu X, Chng WJ, Watson M, Lim YW, Wong CI, Iau P, Sukri N, Lim SE, Yap HL, Buhari SA, Tan P, Guo J, Chuah B, McLeod HL, Goh BC. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenet Genomics. 2009 Nov;19(11):833-842. Pubmedid: 19809382.
  • Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist. 2009 Oct;14(10):970-978. Pubmedid: 19828593. Pmcid: PMC2917613.
  • Rossi JS, McLeod HL. The pharmacogenetics of statin therapy: when the body aches, the mind will follow. J Am Coll Cardiol. 2009 Oct;54(17):1617-1618. Pubmedid: 19833261.
  • Hertz DL, McLeod HL, Hoskins JM. Pharmacogenetics of breast cancer therapies. Breast. 2009 Oct;18 Suppl 3:S59-S63. Pubmedid: 19914545.
  • Oliveira E, Pereira R, Amorim A, McLeod H, Prata MJ. Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics. 2009 Sep;10(9):1413-1422. Pubmedid: 19761365.
  • Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009 Sep;27(25):4109-4115. Pubmedid: 19636001. Pmcid: PMC2734422.
  • Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009 Aug;9(8):576-586. Pubmedid: 19629072.
  • Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul;10(7):1139-1146. Pubmedid: 19604089. Pmcid: PMC2748108.
  • Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB. Etoposide pathway. Pharmacogenet Genomics. 2009 Jul;19(7):552-553. Pubmedid: 19512958.
  • Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009 Jul;30(7):375-386. Pubmedid: 19540002.
  • Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009 Jul;74(3):673-688. Pubmedid: 19480968.
  • Marsh S, McLeod H, Dolan E, Shukla SJ, Rabik CA, Gong L, Hernandez-Boussard T, Lou XJ, Klein TE, Altman RB. Platinum pathway. Pharmacogenet Genomics. 2009 Jul;19(7):563-564. Pubmedid: 19525887.
  • Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul;27(21):3540-3546. Pubmedid: 19470925. Pmcid: PMC2717760.
  • Hoskins JM, Roederer MW, McLeod HL. Nevirapine hypersensitivity reaction: will the real HLA please stand up?. Curr Opin Mol Ther. 2009 Jun;11(3):226-230. Pubmedid: 19479655.
  • Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, Schrag D, Schulman KA, Scott J. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics. 2009 Jun;12(4):233-244. Pubmedid: 19367091. Pmcid: PMC2844634.
  • Peters EJ, Kraja AT, Lin SJ, Yen-Revollo JL, Marsh S, Province MA, McLeod HL. Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics. 2009 May;19(5):399-401. Pubmedid: 19339911.
  • Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol. 2009 May;27(15):2419-2421. Pubmedid: 19364959.
  • Gresham V, McLeod HL. Genomics: applications in mechanism elucidation. Adv Drug Deliv Rev. 2009 May;61(5):369-374. Pubmedid: 19166886. Pmcid: PMC2698023.
  • Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn. 2009 May;11(3):216-225. Pubmedid: 19324988. Pmcid: PMC2671339.
  • McWhinney SR, McLeod HL. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics. 2009 Mar;10(3):489-493. Pubmedid: 19650256. Pmcid: PMC2722037.
  • Walko CM, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol. 2009 Mar;6(3):153-162. Pubmedid: 19174777.
  • Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, Yap HL, Yeo WL, Tan P, Tan SH, McLeod H, Goh BC. Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics. 2009 Mar;19(3):181-192. Pubmedid: 19352302.
  • Gurwitz D, McLeod HL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics. 2009 Feb;10(2):157-159. Pubmedid: 19207015.
  • Crowley JJ, Sullivan PF, McLeod HL. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics. 2009 Feb;10(2):161-163. Pubmedid: 19207016. Pmcid: PMC3893087.
  • McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-16. Pubmedid: 19139108. Pmcid: PMC2651829.
  • Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. Pubmedid: 19203892.
  • Auman JT, McLeod HL. Applications of genomic tools to colorectal cancer therapeutics. Curr Opin Mol Ther. 2008 Dec;10(6):548-554. Pubmedid: 19051132.
  • Hutz JE, Kraja AT, McLeod HL, Province MA. CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol. 2008 Dec;32(8):779-790. Pubmedid: 18613097.
  • Sanoff HK, McLeod HL. Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Semin Colon Rectal Surg. 2008 Dec;19(4):226-230. Pubmedid: 19956343. Pmcid: PMC2614280.
  • Yen-Revollo JL, Auman JT, McLeod HL. Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics. 2008 Nov;9(11):1639-1645. Pubmedid: 19018720. Pmcid: PMC2632586.
  • Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics. 2008 Nov;9(11):1573-1577. Pubmedid: 19018710.
  • Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, McLeod HL, Yokoi T. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics. 2008 Oct;18(10):911-920. Pubmedid: 18794728.
  • Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 Oct;9(10):1543-1546. Pubmedid: 18855540. Pmcid: PMC2586963.
  • Yu J, Freimuth RR, Culverhouse R, Marsh S, Watson MA, McLeod HL. DNA methylotype analysis in colorectal cancer. Oncol Rep. 2008 Oct;20(4):921-927. Pubmedid: 18813836.
  • Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008 Oct;14(19):5967-5976. Pubmedid: 18829475. Pmcid: PMC2744124.
  • Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol. 2008 Oct;19(10):1742-1748. Pubmedid: 18534963.
  • Cresci S, Jones PG, Sucharov CC, Marsh S, Lanfear DE, Garsa A, Courtois M, Weinheimer CJ, Wu J, Province MA, Kelly DP, McLeod HL, Spertus JA. Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008 Oct;9(10):1403-1417. Pubmedid: 18855529. Pmcid: PMC2586954.
  • Yu J, Miller R, Zhang W, Sharma M, Holtschlag V, Watson MA, McLeod HL. Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics. 2008 Oct;9(10):1459-1466. Pubmedid: 18855534. Pmcid: PMC2575840.
  • Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep;84(3):326-331. Pubmedid: 18305455. Pmcid: PMC2683977.
  • Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008 Sep;14(17):5594-5601. Pubmedid: 18765553.
  • Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, Mcleod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer. 2008 Aug;44(12):1754-1760. Pubmedid: 18653328. Pmcid: PMC2566790.
  • Deverka PA, McLeod HL. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther. 2008 Aug;84(2):191-193. Pubmedid: 18679180.
  • Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K. Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Pharmacotherapy. 2008 Jul;28(7):821-833. Pubmedid: 18576897.
  • Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 Jul;7(7):568-574. Pubmedid: 18587383. Pmcid: PMC2682785.
  • Hayes DN, McLeod HL. EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose. Ann Oncol. 2008 Jun;19(6):1036-1037. Pubmedid: 18508859.
  • Crowley JJ, Sullivan PF, McLeod HL. Untapped resources for pharmacogenomic discovery in psychiatry. Curr Opin Mol Ther. 2008 Jun;10(3):205-206. Pubmedid: 18535926. Pmcid: PMC3893089.
  • Sureban SM, May R, George RJ, Dieckgraefe BK, McLeod HL, Ramalingam S, Bishnupuri KS, Natarajan G, Anant S, Houchen CW. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008 May;134(5):1448-1458. Pubmedid: 18471519.
  • Cahan P, Godfrey LE, Eis PS, Richmond TA, Selzer RR, Brent M, McLeod HL, Ley TJ, Graubert TA. wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res. 2008 May;36(7):e41. Pubmedid: 18334530. Pmcid: PMC2367727.
  • Walko CM, McLeod HL. Will we ever be ready for blood level-guided therapy?. J Clin Oncol. 2008 May;26(13):2078-2079. Pubmedid: 18445837.
  • Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, McLeod HL. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheum. 2008 Apr;35(4):572-579. Pubmedid: 18381794.
  • Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res. 2008 Mar;14(6):1788-1796. Pubmedid: 18347181.
  • Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. Clin Cancer Res. 2008 Jan;14(1):8-13. Pubmedid: 18172246.
  • Auman JT, McLeod HL. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. Drug Metab Rev. 2008;40(2):303-315. Pubmedid: 18464047.
  • Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA. A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat. 2008;18(6):1150-1177. Pubmedid: 18991114. Pmcid: PMC2790052.
  • Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang W, McLeod H. MAGED2: a novel p53-dissociator. Int J Oncol. 2007 Nov;31(5):1205-1211. Pubmedid: 17912449.
  • Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang W, McLeod H. MAGED2: a novel p53-dissociator. Int J Oncol. 2007 Nov;31(5):1205-1211.
  • Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR, North Central Cancer Treatment Group (N0044), . Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 2007 Oct;30(5):507-513.
  • Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician. 2007 Oct;76(8):1179-1182.
  • Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007 Oct;7(5):362-365.
  • Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 2007 Oct;30(5):507-513. Pubmedid: 17921712.
  • Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007 Oct;25(29):4528-4535. Pubmedid: 17925548.
  • Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician. 2007 Oct;76(8):1179-1182. Pubmedid: 17990842.
  • Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007 Oct;7(5):362-365. Pubmedid: 17224914.
  • Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. J Clin Oncol. 2007 Oct;25(29):4528-4535.
  • Lanfear DE, Jones PG, Marsh S, Cresci S, Spertus JA, McLeod HL. Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Am Heart J. 2007 Sep;154(3):561-566.
  • Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007 Sep;5(99):1290-1295.
  • Lanfear DE, Jones PG, Marsh S, Cresci S, Spertus JA, McLeod HL. Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Am Heart J. 2007 Sep;154(3):561-566. Pubmedid: 17719307.
  • Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007 Sep;99(17):1290-1295. Pubmedid: 17728214.
  • Lanfear DE, Jones PG, Marsh S, Cresci S, Spertus JA, McLeod HL. Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Lanfear DE, Jones PG, Marsh S, Cresci S, Spertus JA, McLeod HL. Am Heart J. 2007 Sep;154(3):561-566.
  • Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics. 2007 Jul;8(7):703-712. Pubmedid: 18240903.
  • McLeod HL. Drug pathways: one gene is not enough. Curr Opin Mol Ther. 2007 Jun;9(3):214-215.
  • McLeod HL. Drug pathways: one gene is not enough. Curr Opin Mol Ther. 2007 Jun;9(3):214-215. Pubmedid: 17608018.
  • Graubert TA, Cahan P, Edwin D, Selzer RR, Richmond TA, Eis PS, Shannon WD, Li X, McLeod HL, Cheverud JM, Ley TJ. A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet. 2007 Jun;3(1):e3. Pubmedid: 17206864. Pmcid: PMC1761046.
  • King CR, Xiao M, Yu J, Minton MR, Addleman NJ, Van Booven DJ, Kwok PY, McLeod HL, Marsh S. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol. 2007 Jun;63(6):547-554.
  • Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenomics. 2007 Jun;8(7):703-712.
  • King CR, Xiao M, Yu J, Minton MR, Addleman NJ, Van Booven DJ, Kwok PY, McLeod HL, Marsh S. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol. 2007 Jun;63(6):547-554. Pubmedid: 17404718.
  • Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics. 2007 May;8(5):519. Pubmedid: 17465717.
  • Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics. 2007 May;8(5):519-519.
  • Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol. 2007 May;59(6):839-845.
  • Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol. 2007 May;59(6):839-845. Pubmedid: 17119966.
  • Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines?. Eur J Cancer. 2007 Apr;43(6):1011-1016. Pubmedid: 17350823.
  • Fukami T, Nakajima M, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos. 2007 Apr;35(4):515-520. Pubmedid: 17267622.
  • Fukami T, Nakajima M, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos. 2007 Apr;35(4):515-520.
  • Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep. 2007 Apr;17(4):853-857. Pubmedid: 17342327.
  • Gurwitz D, McLeod HL. Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics. 2007 Apr;8(4):311-314.
  • Gurwitz D, McLeod HL. Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics. 2007 Apr;8(4):311-314. Pubmedid: 17391068.
  • Lim WT, Zhang W, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod H. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep. 2007 Apr;17(4):853-857.
  • Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines?. Eur J Cancer. 2007 Apr;43(6):1011-1016.
  • Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Wang L, Weinshilboum RM, Weiss ST, Zineh I, Pharmacogenetics Research Network, , . The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar;81(3):328-345.
  • Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar;81(3):328-345. Pubmedid: 17339863.
  • Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 2007 Feb;8(2):119-127.
  • Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007 Feb;21(1):55-62. Pubmedid: 17340039.
  • Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007 Feb;21(1):55-62.
  • Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 2007 Feb;8(2):119-127. Pubmedid: 17257083.
  • de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007 Jan;81(1):42-49. Pubmedid: 17185998.
  • Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol. 2007 Jan;5(1):9-14. Pubmedid: 17265780.
  • Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007 Jan;81(1):76-82. Pubmedid: 17186002.
  • de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007 Jan;81(1):42-49.
  • Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol. 2007 Jan;5(1):9-14.
  • Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther. 2007 Jan;81(1):76-82.
  • Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J. 2007 Jan;6(6):401-412. Pubmedid: 16636685.
  • McLeod H. Graying anatomy? Toward molecular tumor characterization. Pharmacogenomics. 2007 Jan;8(1):15-16.
  • McLeod H. Graying anatomy? Toward molecular tumor characterization. Pharmacogenomics. 2007 Jan;8(1):15-16. Pubmedid: 17187503.
  • Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets. 2006 Dec;7(12):1641-1648. Pubmedid: 17168839.
  • Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets. 2006 Dec;7(12):1641-1648.
  • Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J. 2006 Nov;6(6):401-412.
  • Ambrosone CB, Rebbeck TR, Morgan GJ, Albain KS, Calle EE, Evans WE, Hayes DF, Kushi LH, McLeod HL, Rowland JH, Ulrich CM. New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2042-2046. Pubmedid: 17119026.
  • Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, Cummings K, McLeod HL, Govindan R. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol. 2006 Nov;1(9):972-978.
  • Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, Cummings K, McLeod HL, Govindan R. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol. 2006 Nov;1(9):972-978. Pubmedid: 17409981.
  • Ambrosone CB, Rebbeck TR, Morgan GJ, Albain KS, Calle EE, Evans WE, Hayes DF, Kushi LH, McLeod HL, Rowland JH, Ulrich CM. New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2042-2046.
  • Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod H, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST, Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov;145(10):749-757.
  • Lanfear DE, Spertus JA, McLeod HL. Beta2-adrenergic receptor genotype predicts survival: implications and future directions. J Cardiovasc Nurs. 2006 Nov;21(6):474-477.
  • Marsh S, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep. 2006 Nov;9(2):231-234. Pubmedid: 11836585.
  • Lanfear DE, Spertus JA, McLeod HL. Beta2-adrenergic receptor genotype predicts survival: implications and future directions. J Cardiovasc Nurs. 2006 Nov;21(6):474-477.
  • Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov;145(10):749-757. Pubmedid: 17116919.
  • Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006 Oct;12(20 Pt 1):6094-6099. Pubmedid: 17062685.
  • Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006 Oct;12(20 PT 1):6094-9099.
  • Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol Sci. 2006 Sep;27(9):498-502. Pubmedid: 16876261.
  • O'Neil BH, McLeod HL. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?. J Clin Oncol. 2006 Sep;24(25):4051-4053. Pubmedid: 16943521.
  • Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol Sci. 2006 Sep;27(9):498-502.
  • O'Neil BH, McLeod HL. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?. J Clin Oncol. 2006 Sep;24(25):4051-4053.
  • Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs. 2006 Sep;24(5):393-401.
  • Yu J, Mallon MA, Zhang W, Freimuth RR, Marsh S, Watson MA, Goodfellow PJ, McLeod HL. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res. 2006 Sep;12(17):5104-5111.
  • Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006 Sep;80(3):282-297.
  • Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006 Sep;80(3):282-297. Pubmedid: 16952495.
  • Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs. 2006 Sep;24(5):393-401. Pubmedid: 16505951.
  • Yu J, Mallon MA, Zhang W, Freimuth RR, Marsh S, Watson MA, Goodfellow PJ, McLeod HL. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res. 2006 Sep;12(17):5104-5111. Pubmedid: 16951227.
  • Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care?. Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1681-1683.
  • Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care?. Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1681-1683. Pubmedid: 16857956.
  • Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res. 2006 Jul;12(13):4127-4127.
  • Knoche E, McLeod HL, Graubert TA. Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics. 2006 Jul;7(5):719-729.
  • Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res. 2006 Jul;12(13):4127. Pubmedid: 16818714.
  • Knoche E, McLeod HL, Graubert TA. Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics. 2006 Jul;7(5):719-729. Pubmedid: 16886897.
  • Yu J, McLeod HL, Ezzeldin HH, Diasio RB. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 2006 Jun;12(12):3864-3864.
  • Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun;12(11 Pt2):3612s-3616s.
  • Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. Expression of drug pathway proteins is independent of tumour type. J Pathol. 2006 Jun;209(2):213-219.
  • Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics. 2006 Jun;7(4):625-631.
  • Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. Expression of drug pathway proteins is independent of tumour type. J Pathol. 2006 Jun;209(2):213-219. Pubmedid: 16508919.
  • Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics. 2006 Jun;7(4):625-631. Pubmedid: 16753009.
  • Yu J, McLeod HL, Ezzeldin HH, Diasio RB. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 2006 Jun;12(12):3864. Pubmedid: 16778115.
  • Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun;12(11 Pt 2):3612s-3616s. Pubmedid: 16740794.
  • Brown DB, Cai SR, Fundakowski CE, Zamboni WC, Strychor S, McLeod HL. Pharmacokinetics after endovascular lung perfusion with Cisplatin. J Vasc Interv Radiol. 2006 May;17(5):883-888. Pubmedid: 16687755.
  • Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006 May;66(10):5029-5038. Pubmedid: 16707424.
  • Brown DB, Cai SR, Fundakowski CE, Zamboni WC, Strychor S, McLeod HL, . Pharmacokinetics after endovascular lung perfusion with Cisplatin. J Vasc Interv Radiol. 2006 May;17(5):883-888.
  • Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006 May;66(10):5029-5038.
  • Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006 May;15(66):5029-5038.
  • Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006 May;54(5):1366-1377. Pubmedid: 16645965.
  • Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet. 2006 Apr;15 Spec No 1:R89-R93. Pubmedid: 16651374.
  • McLeod HL. Individualizing cancer chemotherapy. Clin Adv Hematol Oncol. 2006 Apr;4(4):259-261.
  • McLeod HL. Individualizing cancer chemotherapy. Clin Adv Hematol Oncol. 2006 Apr;4(4):259-261. Pubmedid: 16728935.
  • Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci. 2006 Mar;27(4):311-319. Pubmedid: 16376528.
  • Cahan P, Marsh S, McLeod HL. Systems pharmacogenomics in yeast. Pharmacogenomics. 2006 Mar;7(2):255-259. Pubmedid: 16515406.
  • Grice GR, Seaton TL, Woodland AM, McLeod HL. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics. 2006 Jan;7(1):61-65. Pubmedid: 16354125.
  • Freimuth RR, Xiao M, Marsh S, Minton M, Addleman N, Van Booven DJ, McLeod HL, Kwok PY. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet. 2005 Dec;14(23):3595-3603. Pubmedid: 16239245.
  • Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics. 2005 Dec;6(8):873-877. Pubmedid: 16296950.
  • Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005 Nov;11(22):8097-8104. Pubmedid: 16299241.
  • McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Clin Infect Dis. 2005 Nov;41 Suppl 7:S449-S452. Pubmedid: 16237646.
  • Hoskins JM, Marsh S, McLeod HL. Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos. 2005 Oct;33(10):1564-1565. Pubmedid: 16166400.
  • Walgren RA, Meucci MA, McLeod HL. Pharmacogenomic discovery approaches: will the real genes please stand up?. J Clin Oncol. 2005 Oct;23(29):7342-7349. Pubmedid: 16145062.
  • Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005 Oct;65(19):8961-8967. Pubmedid: 16204069.
  • Maxwell TJ, Ameyaw MM, Pritchard S, Thornton N, Folayan G, Githang'a J, Indalo A, Tariq M, Mobarek A, Evans DA, Ofori-Adjei D, Templeton AR, McLeod HL. Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med. 2005 Oct;16(4):573-580. Pubmedid: 16142389.
  • Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005 Sep;294(12):1526-1533. Pubmedid: 16189366.
  • Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005 Sep;16(8):797-803. Pubmedid: 16096426.
  • Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol. 2005 Sep;70(5):801-808. Pubmedid: 15993850.
  • McLeod HL, Marsh S. Pharmacogenetics goes 3D. Nat Genetics. 2005 Aug;37(8):794-795. Pubmedid: 16049504.
  • Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos. 2005 Aug;33(8):1202-1210. Pubmedid: 15900015.
  • Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Brit J Cancer. 2005 Jul;93(1):46-53. Pubmedid: 15942626. Pmcid: PMC2361488.
  • Cai SR, Garbow JR, Culverhouse R, Church RD, Zhang W, Shannon WD, McLeod HL. A mouse model for developing treatment for secondary liver tumors. Int J Oncol. 2005 Jul;27(1):113-120. Pubmedid: 15942650.
  • Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005 Jul;6(5):503-513. Pubmedid: 16014000.
  • Wood ET, Stover DA, Ehret C, Destro-Bisol G, Spedini G, McLeod H, Louie L, Bamshad M, Strassmann BI, Soodyall H, Hammer MF. Contrasting patterns of Y chromosome and mtDNA variation in Africa: evidence for sex-biased demographic processes. Eur J Hum Genet. 2005 Jul;13(7):867-876. Pubmedid: 15856073.
  • Zhang W, Hart J, McLeod HL, Wang HL. Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol. 2005 Jul;124(1):11-19. Pubmedid: 15923159.
  • Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 Jun;352(22):2285-2293. Pubmedid: 15930419.
  • Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Mol Cancer Ther. 2005 May;4(5):843-854. Pubmedid: 15897249.
  • Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005 May;6:19. Pubmedid: 15882469. Pmcid: PMC1142317.
  • Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res. 2005 Apr;11(7):2612-2619. Pubmedid: 15814641.
  • Fox CA, Sapinoso LM, Zhang H, Zhang W, McLeod HL, Petroni GR, Mullick T, Moskaluk CA, Frierson HF, Hampton GM, Powell SM. Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas. Neoplasia. 2005 Apr;7(4):407-416. Pubmedid: 15967118. Pmcid: PMC1501154.
  • Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005 Apr;93(4):700-705. Pubmedid: 15841315.
  • Walgren RA, McLeod HL. Small inhibitory RNA--a tool for credentialing candidate genes. Pharmacogenomics. 2005 Apr;6(3):281-292. Pubmedid: 16013959.
  • Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res. 2005 Mar;11(5):2053-2062. Pubmedid: 15756032.
  • Freimuth RR, Stormo GD, McLeod HL. PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat. 2005 Feb;25(2):110-117. Pubmedid: 15643605.
  • Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol. 2005 Feb;32(1):113-119. Pubmedid: 15726513.
  • Ranganathan P, McLeod HL. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer. Arthritis Rheum. 2005 Feb;52(2):670-671. Pubmedid: 15692997.
  • Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Brit J Cancer. 2005 Jan;92(2):259-264. Pubmedid: 15655543. Pmcid: PMC2361854.
  • Meucci MA, Marsh S, Watters JW, McLeod HL. CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics. 2005 Jan;6(1):59-63. Pubmedid: 15723606.
  • Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet. 2005 Jan;49(10):579-581. Pubmedid: 15322947.
  • Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol. 2005;311:97-114. Pubmedid: 16100402.
  • King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J. 2005;5(1):54-59. Pubmedid: 15534626.
  • Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. Pubmedid: 15762770.
  • Read W, McLeod H, Govindan R. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):15-17. Pubmedid: 15685828.
  • Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther. 2004 Dec;76(6):519-527. Pubmedid: 15592323.
  • Watters JW, McLeod HL. Candidate gene selection in pharmacogenomics: biology leads the way. Pharmacogenomics. 2004 Dec;5(8):1019-1022. Pubmedid: 15584871.
  • Lim WT, McLeod HL. Should screening for DPD deficiency be mandatory before 5-FU exposure?. Onkologie. 2004 Dec;27(6):531-533. Pubmedid: 15603058.
  • Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, Hanna N, Stoner C, Ansari R, Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):18-21. Pubmedid: 15685829.
  • Rooney PH, Boonsong A, McFadyen MC, McLeod HL, Cassidy J, Curran S, Murray GI. The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol. 2004 Nov;204(3):282-288. Pubmedid: 15476264.
  • Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics. 2004 Oct;5(7):835-843. Pubmedid: 15469406.
  • Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004 Oct;84(4):661-668. Pubmedid: 15475243.
  • Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, van Groeningen CJ, Pinedo HM, Peters GJ. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1381-1384. Pubmedid: 15571263.
  • Mauritz R, Schwabe W, Haeusler P, Noordhuis P, Smid K, McLeod HL, Behnke D, van Groeningen CJ, Peters GJ. Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1471-1474. Pubmedid: 15571279.
  • Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2004 Oct;26(5):524-528. Pubmedid: 15385835.
  • Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet. 2004 Sep;5(9):676-680. Pubmedid: 15372090.
  • de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res. 2004 Sep;10(17):5889-5894. Pubmedid: 15355921.
  • Church RD, Yu J, Fleshman JW, Shannon WD, Govindan R, McLeod HL. RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. Brit J Cancer. 2004 Sep;91(6):1015-1018. Pubmedid: 15328521. Pmcid: PMC2747709.
  • Lanfear DE, Marsh S, McLeod HL. Caution with beta1-adrenergic receptor genotyping. Clin Pharmacol Ther. 2004 Aug;76(2):185-186. Pubmedid: 15289795.
  • Xu JM, Paradiso A, McLeod HL. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?. Eur J Cancer. 2004 Aug;40(12):1807-1809. Pubmedid: 15288280.
  • Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A. 2004 Aug;101(32):11809-11814. Pubmedid: 15282376. Pmcid: PMC511056.
  • Sparreboom A, Marsh S, Mathijssen RH, Verweij J, McLeod HL. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs. 2004 Aug;22(3):285-289. Pubmedid: 15122075.
  • Lanfear DE, Marsh S, Cresci S, Shannon WD, Spertus JA, McLeod HL. Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. J Am Coll Cardiol. 2004 Jul;44(1):165-167. Pubmedid: 15234427.
  • Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, McLeod HL. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics. 2004 Jul;5(5):559-569. Pubmedid: 15212592.
  • Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett. 2004 Jul;569(1-3):75-81. Pubmedid: 15225612.
  • Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004 Jul;76(1):38-44. Pubmedid: 15229462.
  • Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis. 2004 Jul;39(1):98-106. Pubmedid: 15206060.
  • Lanfear DE, Marsh S, Cresci S, Spertus JA, McLeod HL. Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. Pharmacogenomics. 2004 Jul;5(5):553-558. Pubmedid: 15212591.
  • McLeod HL, King CR, Marsh S. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S43-S47. Pubmedid: 15212705.
  • Zhao T, Chang LW, McLeod HL, Stormo GD. PromoLign: a database for upstream region analysis and SNPs. Hum Mutat. 2004 Jun;23(6):534-539. Pubmedid: 15146456.
  • Hou W, Watters JW, McLeod HL. Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May;804(2):263-267. Pubmedid: 15081919.
  • Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 2004 May;14(5):329-332. Pubmedid: 15115919.
  • Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004 May;22(9):1564-1571. Pubmedid: 15051756.
  • Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J. 2004 Apr;25(4):447-451. Pubmedid: 15083213.
  • McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene?. J Clin Oncol. 2004 Apr;22(8):1356-1359. Pubmedid: 15007084.
  • Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 2004 Apr;24(4):893-900. Pubmedid: 15010827.
  • McLeod HL. Current overview of pharmacogenetics. Clin Adv Hematol Oncol. 2004 Apr;2(4):205-207. Pubmedid: 16163181.
  • Watters JW, Zhang W, Meucci MA, Hou W, Ma MK, McLeod HL. Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics. 2004 Apr;14(4):247-254. Pubmedid: 15083069.
  • Voora D, McLeod HL, Eby C, Gage BF. Use of pharmacogenetics to guide warfarin therapy. Drugs Today (Barc). 2004 Mar;40(3):247-257. Pubmedid: 15148533.
  • McLeod HL. Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics. 2004 Mar;5(2):139-141. Pubmedid: 15016603.
  • Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res. 2004 Feb;10(3):1121-1129. Pubmedid: 14871992.
  • Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004 Jan;91(1):87-94. Pubmedid: 14691573.
  • Marsh S, McLeod HL. Cancer pharmacogenetics. Brit J Cancer. 2004 Jan;90(1):8-11. Pubmedid: 14710198. Pmcid: PMC2395337.
  • Brown DB, Ma MK, Battafarano RJ, Naidu S, Pluim D, Zamboni WC, McLeod HL. Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model. Oncol Rep. 2004 Jan;11(1):237-243. Pubmedid: 14654932.
  • Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov. 2004 Jan;3(1):88-93. Pubmedid: 14708023.
  • Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem. 2004;4(13):1399-1409. Pubmedid: 15379653.
  • Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J. 2004;4(5):307-314. Pubmedid: 15224082.
  • McLeod HL, Watson MA. Molecular therapeutics: are we making progress?. Curr Opin Mol Ther. 2003 Dec;5(6):573-574. Pubmedid: 14755882.
  • Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003 Dec;3(12):912-920. Pubmedid: 14740638.
  • Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M, DiPersio JF, Link DC, Tomasson MH, Graubert TA, McLeod H, Khoury H, Watson M, Shannon W, Trinkaus K, Heath S, Vardiman JW, Caligiuri MA, Bloomfield CD, Milbrandt JD, Mardis ER, Wilson RK. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A. 2003 Nov;100(24):14275-14280. Pubmedid: 14614138. Pmcid: PMC283582.
  • Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dipersio JF. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003 Nov;9(11):714-721. Pubmedid: 14652855.
  • Watters JW, Kloss EF, Link DC, Graubert TA, McLeod HL. A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985). 2003 Oct;95(4):1352-1360. Pubmedid: 12970373.
  • Yu J, Marsh S, Ahluwalia R, McLeod HL. Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res. 2003 Oct;63(19):6170-6173. Pubmedid: 14559799.
  • Ahluwalia R, Freimuth R, McLeod HL, Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem. 2003 Oct;49(10):1661-1664. Pubmedid: 14500593.
  • Govindan R, Read W, Faust J, Trinkaus K, Ma MK, Baker SD, McLeod HL, Perry MC. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):27-31. Pubmedid: 14569845.
  • Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg. 2003 Sep;90(9):1055-1067. Pubmedid: 12945071.
  • Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003 Aug;9(9):3246-3253. Pubmedid: 12960109.
  • Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL, Abad A. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol. 2003 May;22(5):945-953. Pubmedid: 12684658.
  • Marsh S, McLeod HL. Crohn's disease: ethnic variation in CARD15 genotypes. Gut. 2003 May;52(5):770. Pubmedid: 12692072. Pmcid: PMC1773649.
  • Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003 Apr;104(4):504-511. Pubmedid: 12584750.
  • Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta. 2003 Mar;1603(2):99-111. Pubmedid: 12618310.
  • Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Brit J Cancer. 2003 Mar;88(6):928-932. Pubmedid: 12644831. Pmcid: PMC2377095.
  • Watters JW, McLeod HL. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol Sci. 2003 Feb;24(2):55-58. Pubmedid: 12559764.
  • Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003 Feb;348(6):538-549. Pubmedid: 12571262.
  • McLeod HL, Papageorgio C, Watters JW. Using genetic variation to optimize cancer chemotherapy. Clin Adv Hematol Oncol. 2003 Feb;1(2):107-111. Pubmedid: 16224389.
  • Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis. 2003 Jan;62(1):4-9. Pubmedid: 12480661. Pmcid: PMC1754300.
  • Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem. 2003 Jan;10(1):41-49. Pubmedid: 12570720.
  • Rose CM, Marsh S, Ameyaw MM, McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol Med. 2003;85:225-237. Pubmedid: 12710211.
  • McLeod HL, Church RD. Molecular predictors of prognosis and response to therapy in colorectal cancer. Cancer Chemother Biol Response Modif. 2003;21:791-801. Pubmedid: 15338774.
  • McLeod HL, Yu J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest. 2003;21(4):630-640. Pubmedid: 14533451.
  • Zhang W, Xu G, McLeod HL. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):374-380. Pubmedid: 12607608.
  • Watters JW, McLeod HL. Recent advances in the pharmacogenetics of cancer chemotherapy. Curr Opin Mol Ther. 2002 Dec;4(6):565-571. Pubmedid: 12596358.
  • Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm. 2002 Nov;59(21):2061-2069. Pubmedid: 12434718.
  • Watters JW, McLeod HL. Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics. 2002 Nov;3(6):781-790. Pubmedid: 12437480.
  • Siva C, Yokoyama WM, McLeod HL. Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. Rheumatology (Oxford). 2002 Nov;41(11):1273-1279. Pubmedid: 12422000.
  • Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol. 2002 Nov;21(5):1119-1124. Pubmedid: 12370763.
  • McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002 Nov;38(17):2258-2264. Pubmedid: 12441262.
  • Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol. 2002 Nov;33(11):1114-1119. Pubmedid: 12454816.
  • Reif S, Nicolson MC, Bisset D, Reid M, Kloft C, Jaehde U, McLeod HL. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol. 2002 Oct;58(7):491-494. Pubmedid: 12389073.
  • Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat. 2002 Sep;20(3):174-179. Pubmedid: 12203989.
  • Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res. 2002 Aug;8(8):2605-2611. Pubmedid: 12171891.
  • Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002 Jul;1587(2-3):194-205. Pubmedid: 12084461.
  • McLeod HL. Genetic strategies to individualize supportive care. J Clin Oncol. 2002 Jun;20(12):2765-2767. Pubmedid: 12065551.
  • Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002 May;9(3):653-655. Pubmedid: 11956645.
  • Ma MK, McLeod HL, Westervelt P, Fracasso PM. Pharmacokinetic study of infusional valspodar. J Clin Pharmacol. 2002 Apr;42(4):412-418. Pubmedid: 11936566.
  • McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray GI. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol. 2002 Apr;196(4):386-393. Pubmedid: 11920733.
  • McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev Anticancer Ther. 2002 Feb;2(1):113-119. Pubmedid: 12113060.
  • McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, McLeod HL. c-erbB-2 is not a major factor in the development of colorectal cancer. Brit J Cancer. 2002 Feb;86(4):568-573. Pubmedid: 11870539. Pmcid: PMC2375271.
  • McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics. 2002 Jan;3(1):89-98. Pubmedid: 11966406.
  • McLeod HL. Pharmacokinetic differences between ethnic groups. Lancet. 2002 Jan;359(9300):78. Pubmedid: 11809218.
  • Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001 Nov;7(11):3314-3324. Pubmedid: 11705842.
  • Rooney PH, Boonsong A, McKay JA, Marsh S, Stevenson DA, Murray GI, Curran S, Haites NE, Cassidy J, McLeod HL. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Brit J Cancer. 2001 Nov;85(10):1492-1498. Pubmedid: 11720434. Pmcid: PMC2363933.
  • McLeod HL. Pharmacogenetics: more than skin deep. Nat Genetics. 2001 Nov;29(3):247-248. Pubmedid: 11687789.
  • Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer. 2001 Nov;1(3):175-178. Pubmedid: 12450432.
  • Collie-Duguid ES, Johnston SJ, Boyce L, Smith N, Cowieson A, Cassidy J, Murray GI, McLeod HL. Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer. 2001 Oct;94(2):297-301. Pubmedid: 11668512.
  • McLeod HL. Race and responsiveness to drugs for heart failure. N Engl J Med. 2001 Sep;345(10):766-767. Pubmedid: 11547749.
  • Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol. 2001 Aug;54(4):253-258. Pubmedid: 11477141. Pmcid: PMC1187077.
  • Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol. 2001 Aug;19(2):383-386. Pubmedid: 11445856.
  • McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001 Jul;62(2):207-212. Pubmedid: 11389879.
  • Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res. 2001 Jul;61(14):5505-5510. Pubmedid: 11454699.
  • McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, Parkin D, Murray GI. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Brit J Cancer. 2001 Jul;85(2):242-246. Pubmedid: 11461084. Pmcid: PMC2364045.
  • Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001 Apr;11(3):217-221. Pubmedid: 11337937.
  • Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H, Yamakido M. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics. 2001 Apr;11(3):275-278. Pubmedid: 11337944.
  • Evans DA, McLeod HL, Pritchard S, Tariq M, Mobarek A. Interethnic variability in human drug responses. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):606-610. Pubmedid: 11259361.
  • Pritchard SC, Nicolson MC, Lloret C, McKay JA, Ross VG, Kerr KM, Murray GI, McLeod HL. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep. 2001 Mar;8(2):421-424. Pubmedid: 11182067.
  • Chapman AD, Pritchard SC, Yap WW, Rooney PH, Cockburn JS, Hutcheon AW, Nicolson MC, Kerr KM, McLeod HL. Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer. 2001 Feb;91(4):779-784. Pubmedid: 11241246.
  • Dusseau C, Murray GI, Keenan RA, O'Kelly T, Krokan HE, McLeod HL. Analysis of uracil DNA glycosylase in human colorectal cancer. Int J Oncol. 2001 Feb;18(2):393-399. Pubmedid: 11172609.
  • Balciuniene J, Syvänen AC, McLeod HL, Pettersson U, Jazin EE. The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa. J Mol Evol. 2001 Feb;52(2):157-163. Pubmedid: 11231895.
  • Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther. 2001 Feb;296(2):537-541. Pubmedid: 11160641.
  • Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, Cassidy J. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Brit J Cancer. 2001 Feb;84(3):308-312. Pubmedid: 11161393. Pmcid: PMC2363746.
  • McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101-121. Pubmedid: 11264452.
  • Ameyaw MM, Thornton N, McLeod HL. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000 Dec;92(23):1947. Pubmedid: 11106692.
  • Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics. 2000 Nov;10(8):753-756. Pubmedid: 11186137.
  • McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, McLeod HL. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000 Oct;88(1):77-81. Pubmedid: 10964085.
  • Morsman JM, Sludden J, Ameyaw MM, Githang'A J, Indalo A, Ofori-Adjei D, McLeod HL. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol. 2000 Sep;50(3):269-272. Pubmedid: 10971312. Pmcid: PMC2014976.
  • Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther. 2000 Sep;68(3):270-279. Pubmedid: 11014408.
  • McLeod HL, McKay JA, Collie-Duguid ES, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer. 2000 Aug;36(13 Spec No):1706-1712. Pubmedid: 10959056.
  • Boonsong A, Marsh S, Rooney PH, Stevenson DA, Cassidy J, McLeod HL. Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogen. 2000 Aug;121(1):56-60. Pubmedid: 10958942.
  • Jaffrey RG, Pritchard SC, Clark C, Murray GI, Cassidy J, Kerr KM, Nicolson MC, McLeod HL. Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. Cancer Res. 2000 Aug;60(16):4349-4352. Pubmedid: 10969775.
  • McKay JA, Lloret C, Murray GI, Johnston PG, Bicknell R, Ahmed FY, Cassidy J, McLeod HL. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int J Oncol. 2000 Jul;17(1):153-158. Pubmedid: 10853033.
  • McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 2000 Jul;6(7):2677-2684. Pubmedid: 10914709.
  • Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000 Apr;10(3):217-223. Pubmedid: 10803677.
  • Collie-Duguid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL. Cloning and initial characterization of the human DPYD gene promoter. Biochem Bioph Res Co. 2000 Apr;271(1):28-35. Pubmedid: 10777676.
  • Curran S, McKay JA, McLeod HL, Murray GI. Laser capture microscopy. Mol Pathol. 2000 Apr;53(2):64-68. Pubmedid: 10889904. Pmcid: PMC1186907.
  • McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000 Apr;14(4):567-572. Pubmedid: 10764140.
  • Collie-Duguid ES, McLeod HL, Cassidy J. Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?. Ann Oncol. 2000 Mar;11(3):255-257. Pubmedid: 10811489.
  • McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL. Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res. 2000 Mar;6(3):1113-1118. Pubmedid: 10741741.
  • Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?. Eur J Cancer. 2000 Jan;36(1):37-42. Pubmedid: 10741292.
  • Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-427. Pubmedid: 10803927.
  • McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ES. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999 Dec;9(6):773-776. Pubmedid: 10634140.
  • Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, Maeda H, Yamakido M. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med. 1999 Dec;38(12):944-947. Pubmedid: 10628931.
  • McLeod HL, Murray GI, Mollison J, McKay J, Cassidy J. Selection of markers to predict tumour response or survival: description of a novel approach. Eur J Cancer. 1999 Nov;35(12):1650-1652. Pubmedid: 10674008.
  • McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res. 1999 Oct;5(10):2669-2671. Pubmedid: 10537326.
  • Johnston SJ, Ridge SA, Cassidy J, McLeod HL. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res. 1999 Sep;5(9):2566-2570. Pubmedid: 10499634.
  • Ahmed FY, Johnston SJ, Cassidy J, O'Kelly T, Binnie N, Murray GI, van Gennip AH, Abeling NG, Knight S, McLeod HL. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol. 1999 Aug;17(8):2439-2445. Pubmedid: 10561307.
  • Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics. 1999 Jun;58(3):310-312. Pubmedid: 10373329.
  • McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BE. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Brit J Haematol. 1999 Jun;105(3):696-700. Pubmedid: 10354134.
  • Rooney PH, Murray GI, Stevenson DA, Haites NE, Cassidy J, McLeod HL. Comparative genomic hybridization and chromosomal instability in solid tumours. Brit J Cancer. 1999 May;80(5-6):862-873. Pubmedid: 10360667. Pmcid: PMC2362298.
  • Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999 Feb;8(2):367-370. Pubmedid: 9931345.
  • Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999 Feb;9(1):37-42. Pubmedid: 10208641.
  • McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Brit J Cancer. 1999 Jan;79(2):191-203. Pubmedid: 9888457. Pmcid: PMC2362193.
  • McLeod HL, Milne LH, Johnston SJ. 5-Fluorouracil metabolizing enzymes. Methods Mol Med. 1999;28:111-120. Pubmedid: 21374032.
  • McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ. Nomenclature for human DPYD alleles. Pharmacogenetics. 1998 Dec;8(6):455-459. Pubmedid: 9918128.
  • Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998 Nov;129(9):716-718. Pubmedid: 9841604.
  • Rooney PH, Stevenson DA, Marsh S, Johnston PG, Haites NE, Cassidy J, McLeod HL. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res. 1998 Nov;58(22):5042-5045. Pubmedid: 9823306.
  • McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur J Cancer. 1998 Sep;34(10):1623-1627. Pubmedid: 9893640.
  • Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol. 1998 Aug;46(2):151-156. Pubmedid: 9723824. Pmcid: PMC1873668.
  • Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998 Aug;51(3):391-400. Pubmedid: 9721209.
  • Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol. 1998 Aug;46(2):151-156. Pmcid: PMC1873668.
  • McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 1998 June;45(6):539-544.
  • McLeod HL, Syvänen AC, Githang'a J, Indalo A, Ismail D, Dewar K, Ulmanen I, Sludden J. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics. 1998 June;8(3):195-199.
  • McLeod HL, Syvänen AC, Githang'a J, Indalo A, Ismail D, Dewar K, Ulmanen I, Sludden J. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics. 1998 Jun;8(3):195-199. Pubmedid: 9682265.
  • Sludden J, Hardy SC, VandenBranden MR, Wrighton SA, McLeod HL. Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat, and mouse. Pharmacology. 1998 May;56(5):276-280.
  • Sludden J, Hardy SC, VandenBranden MR, Wrighton SA, McLeod HL. Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse. Pharmacology. 1998 May;56(5):276-280. Pubmedid: 9597696.
  • McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Brit J Cancer. 1998;77(3):461-465. Pubmedid: 9472644. Pmcid: PMC2151304.
  • Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer. 1998;77(3):497-500.
  • Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Brit J Cancer. 1998;77(3):497-500. Pubmedid: 9472650. Pmcid: PMC2151292.
  • McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer. 1998;77(3):461-465.
  • McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol. 1998;42(2):155-159. Pubmedid: 9654116.
  • McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol. 1998;42(2):155-159.
  • McKay JA, Murray GI, Keith WN, McLeod HL. Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. Mol Pathol. 1997 Dec;50(6):322-325. Pubmedid: 9536283. Pmcid: PMC379667.
  • McKay JA, Murray G, Keith WN, McLeod HL. Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. Mol Pathol. 1997 Dec;50(6):322-325.
  • Boyle J, Henderson D, Usher J, McLeod H, McCall J. Exploring novel chemotherapy treatments using the WWW. Int J Med Inform. 1997 Nov;47(1-2):107-114.
  • Wattanatorn W, McLeod HL, Cassidy J, Kendle KE. High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B Biomed Sci Appl. 1997 Apr;692(1):233-237.
  • Wattanatorn W, McLeod HL, Cassidy J, Kendle KE. High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B Biomed Sci Appl. 1997 Apr;692(1):233-237. Pubmedid: 9187406.
  • McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther. 1997;74(1):39-54.
  • Ridge SA, Brown O, McMurrough J, Fernandez-Salguero P, Evans WE, Gonzalez FJ, McLeod HL. Mutations at codon 974 of the DPYD gene are a rare event. Brit J Cancer. 1997;75(2):178-179. Pubmedid: 9010022. Pmcid: PMC2063286.
  • McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther. 1997;74(1):39-54. Pubmedid: 9336015.
  • Ridge SA, Brown O, McMurrough J, Fernandez-Salguero P, Evans WE, Gonzalez FJ, McLeod HL. Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer. 1997;75(2):178-179.
  • McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Brit J Cancer. 1996 Dec;74(12):1944-1948. Pubmedid: 8980394. Pmcid: PMC2074819.
  • McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P, Graham MA. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 1996 Dec;74(11):1714-1718.
  • McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P, Graham MA. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Brit J Cancer. 1996 Dec;74(11):1714-1718. Pubmedid: 8956783. Pmcid: PMC2077212.
  • McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. Multicentre phase II pharmacological evaluation of rhizoxin. Br J Cancer. 1996 Dec;74(12):1944-1948.
  • Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug;98(3):610-615. Pmcid: PMC507468.
  • McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. Eur J Cancer. 1996 Aug;32A(9):1518-1522. Pubmedid: 8911111.
  • McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer. 1996 Aug;74(4):508-512. Pmcid: PMC2074660.
  • Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug;98(3):610-615. Pubmedid: 8698850. Pmcid: PMC507468.
  • McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. Eur J Cancer. 1996 Aug;32A(9):1518-1522.
  • McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Brit J Cancer. 1996 Aug;74(4):508-512. Pubmedid: 8761363. Pmcid: PMC2074660.
  • Howard ML. The ethical and legal ramifications of managed care. Am J Otol. 1996 Jul;17(4):503-505. Pubmedid: 8841693.
  • McLeod HL, Kumar A. Metabolism of azathioprine. Transplantation. 1996 May;61(9):1425-1425.
  • McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol. 1996 May;41(5):425-427. Pubmedid: 8735686. Pmcid: PMC2042607.
  • McLeod HL, Kumar A. Metabolism of azathioprine. Transplantation. 1996 May;61(9):1425. Pubmedid: 8629313.
  • McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol. 1996 May;41(5):425-427. Pmcid: PMC2042607.
  • McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics. 1995 Oct;5(5):281-286. Pubmedid: 8563768.
  • McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics. 1995 Oct;5(5):281-286.
  • McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995 Apr;85(7):1897-1902.
  • McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995 Apr;85(7):1897-1902. Pubmedid: 7703493.
  • McLeod HL. Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity. Eur J Clin Pharmacol. 1995;48(1):85-88.
  • McLeod HL. Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity. Eur J Clin Pharmacol. 1995;48(1):85-88. Pubmedid: 7621855.
  • Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol. 1994 Dec;36(6):920-924.
  • Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol. 1994 Dec;36(6):920-924. Pubmedid: 7998781.
  • McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AG, Kaye SB, Brown R, Keith WN. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 1994 Dec;59(5):607-611. Pubmedid: 7960233.
  • McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AG, Kaye SB, Brown R, Keith WN. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 1994 Dec;59(5):607-611.
  • Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther. 1994 Nov;56(5):503-511.
  • Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther. 1994 Nov;56(5):503-511. Pubmedid: 7955814.
  • McLeod HL. Concordance of phenotype and genotype for CYP2D6. Clin Pharmacol Ther. 1994 Oct;56(4):463-464. Pubmedid: 7955809.
  • McLeod HL. Concordance of phenotype and genotype for CYP2D6. Clin Pharmacol Ther. 1994 Oct;56(4):463-464.
  • Howard ML. Health system reform: the case for a single-payer approach. Jama. 1994 Oct;272(14):1101-1102. Pubmedid: 7933315.
  • McLeod HL, Fang L, Luo X, Scott EP, Evans WE. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther. 1994 July;270(1):26-29.
  • McLeod HL, Fang L, Luo X, Scott EP, Evans WE. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther. 1994 Jul;270(1):26-29. Pubmedid: 8035323.
  • McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994 Jan;55(1):15-20.
  • McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994 Jan;55(1):15-20. Pubmedid: 8299312.
  • McLeod HL. Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?. Eur J Cancer. 1994;30A(14):2039-2041. Pubmedid: 7857699.
  • McLeod HL. Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?. Eur J Cancer. 1994;30A(14):2039-2041.
  • Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest. 1993 May;91(5):2150-2154.
  • McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993 May;341(8853):1151. Pubmedid: 8097831.
  • Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest. 1993 May;91(5):2150-2154. Pubmedid: 8098046. Pmcid: PMC288217.
  • McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993 May;341(8853):1151.
  • Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, Stute N, Crom WR, Evans WE. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol. 1993 Feb;20(1):18-29.
  • McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv. 1993;17:253-268. Pubmedid: 8137343.
  • McLeod HL, Relling MV. Stability of etoposide solution for oral use. Am J Hosp Pharm. 1992 Nov;49(11):2784-2785.
  • McLeod HL, Relling MV. Stability of etoposide solution for oral use. Am J Hosp Pharm. 1992 Nov;49(11):2784-2785. Pubmedid: 1471649.
  • Evans WE, McLeod HL. Pediatric pharmacokinetics and therapeutic drug monitoring. Pediatr Rev. 1992 Nov;13(11):413-421.
  • McLeod HL, Evans WE. Pediatric pharmacokinetics and therapeutic drug monitoring. Pediatr Rev. 1992 Nov;13(11):413-421. Pubmedid: 1289869.
  • McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl. 1992 Aug;s23-s29. Pmcid: PMC2149660.
  • McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl. 1992 Aug;18:S23-S29. Pubmedid: 1503923. Pmcid: PMC2149660.
  • McLeod HL, McGuire TR, Yee GC. Stability of cyclosporine in dextrose 5%, NaCl 0.9%, dextrose/amino acid solution, and lipid emulsion. Ann Pharmacother. 1992 Feb;26(2):172-175.
  • McLeod HL, McGuire TR, Yee GC. Stability of cyclosporine in dextrose 5%, NaCl 0.9%, dextrose/amino acid solution, and lipid emulsion. Ann Pharmacother. 1992 Feb;26(2):172-175. Pubmedid: 1554924.
  • McLeod HL, Relling MV. Stability of etoposide solution at room temperature. Am J Hosp Pharm. 1992;11:2784-2785.
  • Linklater HA, Dzialoszynski T, McLeod HL, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis. XII: Supplemental vitamin A treatment reduces gamma-crystallin leakage from lenses in diabetic rats. Lens Eye Toxic Res. 1992;9(2):115-126. Pubmedid: 1534487.
  • McLeod HL, Baker DK Jr, Pui CH, Rodman JH. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29(2):150-154.
  • McLeod HL, Baker DK, Pui CH, Rodman JH. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer Chemother Pharmacol. 1991;29(2):150-154. Pubmedid: 1760858.
  • Linklater HA, Dzialoszynski T, McLeod HL, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis. XI. Vitamin C reduces gamma-crystallin leakage from lenses in diabetic rats. Exp Eye Res. 1990 Sep;51(3):241-247. Pubmedid: 2401346.
  • Linklater HA, Dzialoszynski T, McLeod HL, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis VIII: effects of butylated hydroxytoluene (BHT) in reducing protein leakage from lenses in diabetic rats. Exp Eye Res. 1986 Sep;43(3):305-314. Pubmedid: 3780876.
  • Lampe RM, Weir MR, McLeod HL, Artalejo L. A clinical trial of antihistamine, decongestant, or placebo in antibiotic-treated acute otitis media followed with pneumatic otoscopy and impedance tympanometry. Mil Med. 1981 Apr;146(4):259-261. Pubmedid: 6784022.
  • O'Connor SK, Ferreri SP, Michaels NM, Chater RW, Viera AJ, Faruki H, McLeod HL, Roederer M. Making pharmacogenetic testing a reality in a community pharmacy. J Am Pharm Assoc (2003). 52(6):e259-e265. Pubmedid: 23229988.
  • Watson RG, McLeod HL. Pharmacogenomic contribution to drug response. Cancer J. 17(2):80-88. Pubmedid: 21427551.
  • Padgett L, O'Connor S, Roederer M, McLeod H, Ferreri S. Pharmacogenomics in a community pharmacy: ACT now. J Am Pharm Assoc (2003). 51(2):189-193. Pubmedid: 21382809.
  • Wattanatorn W, McLeod HL, Macklon F, Reid M, Kendle KE, Cassidy J. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cell in patients with colorectal cancer. Pharmacotherapy. 1997 Sept - Oct;17(5):881-886.
  • Rodriguez DB, Mackin A, Easley R, Boyle CR, Hou W, Langston C, Walsh AM, Province MA, McLeod HL. Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. J Vet Intern Med. 18(3):339-345. Pubmedid: 15188821.
  • Wattanatorn W, McLeod HL, Macklon F, Reid M, Kendle KE, Cassidy J. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Pharmacotherapy. 17(5):881-886. Pubmedid: 9324177.
  • Tayeb MT, Clark C, Murray GI, Sharp L, Haites NE, McLeod HL. Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia. Ann Saudi Med. 24(1):21-26. Pubmedid: 15310009.
  • Bomgaars L, McLeod HL. Pharmacogenetics and pediatric cancer. Cancer J. 11(4):314-323. Pubmedid: 16197721.
  • Lanfear DE, Spertus JA, McLeod HL. Beta2-adrenergic receptor genotype predicts survival: implications and future directions. J Cardiovasc Nurs. 21(6):474-477. Pubmedid: 17293738.
  • McLeod HL, Greenberg HJ. Relationship between loudness discomfort level and acoustic reflex threshold for normal and sensorineural hearing-impaired individuals. J Speech Hear Res. 1979 Dec;22(4):873-883. Pubmedid: 513694.
  • Coe WC, Buckner LG, Howard ML, Kobayashi K. Hypnosis as role enactment: focus on a role specific skill. Am J Clin Hypn. 1972 Jul;15(1):41-45. Pubmedid: 4679790.
  • Stallings JO, Beal DD, Stewart KC, Sessions DG, Howard ML. Total nasal columellar reconstruction. J Laryngol Otol. 1971 Jul;85(7):723-728. Pubmedid: 4932988.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions